Compare Ginkgo Bioworks Holdings Inc (DNA) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs VF Corp — how do they compare? Ginkgo Bioworks Holdings Inc trades at $11.87 (market cap $772.39M), while VF Corp trades at $14.52 (market cap $5.65B). The key difference: VF Corp is far larger — about 7.3× Ginkgo Bioworks Holdings Inc's market cap, and VF Corp pays a 2.5% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and VF Corp for 64 Days on average.
| DNA | VFC | |
|---|---|---|
Market Cap | $772.39M | $5.65B |
Volume | 6,453,273 | 6,542,273 |
Sector | Health | Consumer Cyclical |
52-Week High | $15.83 | $21.55 |
52-Week Low | $5.48 | $12.62 |
Typical Hold Time | 7 Days | 64 Days |
Enterprise Value | $874.34M | $9.94B |
Dividend Yield | — | 2.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported a net loss of $312.76 million on $170.16 million revenue in 2025, with a high gross margin of 68.04% but negative net income margin. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting growth initiatives amid financial challenges.
The outlook remains speculative with significant cash burn and persistent losses, though partnerships and government contracts offer potential catalysts. Risks include high operating costs and reliance on funding, while analyst sentiment is divided equally between buy, hold, and sell ratings. Investment hinges on the company's ability to monetize its technology and achieve profitability.
VFC trades at $14.38, down 0.48% on the day, with a mixed technical picture showing a bullish moving average signal but neutral oscillators. The stock is near its 52-week low, reflecting ongoing challenges. Recent earnings have been volatile, with two misses in the last three quarters, and the company reported a net loss of $189.72 million for 2025. Revenue has declined from $11.8 billion in 2022 to $9.5 billion in 2025, though 2026 projects a return to profitability.
The outlook for VFC hinges on executing its turnaround amid weak Vans performance. The stock's discounted valuation (P/E of 20.84, P/S of 0.6) offers potential upside if brand recovery gains traction, but high execution risk and competitive pressures pose significant threats. Analyst consensus is mixed with a Hold rating, and the stock faces near-term resistance at $15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
